Brayton Purcell LLP

Call For A Free Consultation
800-598-0314

Call For A Free Consultation 800-598-0314

Brayton Purcell LLP
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Videos
  • Contact
  • Home
  • Firm Overview
    • Our Beliefs
      • Giving Back
      • Our Associations And Memberships
      • The Right To Trial By Jury
    • Regions Served
    • Careers
    • Our Employees Pets
    • Press Releases
  • Attorneys
  • Practice Areas
    • Mesothelioma/Asbestos
    • Personal Injury/Wrongful Death
    • Toxic Substances
    • Estate Planning
    • Other Areas Of Practice
  • Court Successes
    • Trial Verdicts
    • Appeals
  • Testimonials
  • Blog
  • Videos
  • Contact

Immunotherapy research shows promise with mesothelioma

On behalf of Brayton Purcell LLP | Dec 6, 2012 | Mesothelioma

Immunotherapy research show promise with mesothelioma

Cancer treatment has made significant advances as more and more is known about how cancer cells function, and what can be done to stop their growth and destroy them. Mesothelioma is an aggressive cancer, often caused by exposure to asbestos fibers. Treating mesothelioma has been less than successful in most cases, and mesothelioma is considered incurable.

Nonetheless, research is continually looking for new methods of treating this deadly disease. Immunotherapy is seen as one potentially promising treatment. Immunotherapy uses the body’s own immune system, which is designed to attack and kill infections within the body, to specifically attack cancer cells.

A recent study from the European Journal of Immunology explains research involving the immune cell, known as the Natural Killer cell (NK cell), to target cancer. This cell has shown anti-tumor ability by killing individual cancer cells.

Unfortunately, as cancer tumors become larger and more solid, the ability of NK to destroy them is diminished. The research team wanted to see if NK cells could be isolated and still be effective. They removed NK cells “from the lung fluid (pleural effusions) of patients with metastatic mesothelioma, lung, breast, uterine, colon, gastric or bladder cancer.”

The researchers found that the NK cells they removed were not “functionally impaired,” suggests that it might be possible to use these NK cells against aggressive cancers like mesothelioma by stimulating the cells. They found that when they were stimulated they showed “a potent cytolytic activity” against cancer cells, meaning they could cause the destruction of the cancer cells.

The scientists conclude that this research “may offer important clues for the development of novel approaches in tumor immunotherapy.”

Source: Surviving Mesothelioma and Cancer Monthly, “Mesothelioma Study Could Improve Immunotherapy,” December 4, 2012

Recent Posts

  • Who is Most at Risk of Mesothelioma?
  • Boiler Room Workers and Asbestos Exposure
  • Mitigating the financial impact of mesothelioma treatments
  • The EPA’s difficulty with data disclosure
  • Judge orders EPA to close loopholes on asbestos-related reporting

Archives

Categories

RSS Feed

Subscribe To This Blog’s Feed

Free Consultation

Take The First Step In Resolving Your Issue. Send Us An Email.

Email Us For A Response

San Francisco
Bay Area Office

222 Rush Landing Road Novato, CA 94945

Novato Office
222 Rush Landing Road
Novato, CA 94945
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions

Southern California
Office

12 28th Street Venice, California 90291

Los Angeles Office
12 28th Street
Venice, California 90291
Toll Free: 800-598-0314
Phone: 415-898-1555
Fax: 415-898-1247

Map & Directions
  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

© 2021 Brayton Purcell LLP. All Rights Reserved.

Disclaimer | Site Map | Privacy Policy | Business Development Solutions by FindLaw, part of Thomson Reuters

Review Us